-

Dexcom to Host Investor Day on December 9, 2020

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business strategy, innovation efforts and long-term financial outlook.

Dexcom will host a live webcast of the event with no pre-registration required, enabling access for all interested stakeholders. The webcast can be accessed at dexcom2020investorday.com, or by navigating to the Dexcom Investor Relations website (https://investors.dexcom.com/) on the Events and Presentations page. A replay of the event will be available shortly after its conclusion.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom to Host Investor Day on December 9, 2020
Release Versions
English

Contacts

Investor Contact:
Steven R. Pacelli 
Executive Vice President, Strategy and Corporate Development 
(858) 200-0200

Media Contact:
James McIntosh
(619) 884-2118
James.mcintosh@dexcom.com

More News From DexCom, Inc.

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights...

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company’s quality control process. Sensors identified...
Back to Newsroom